The clinical potential of sphingolipid-based therapeutics

被引:27
作者
Fox, T. E.
Finnegan, C. M.
Blumenthal, R.
Kester, M.
机构
[1] Natl Canc Inst, Canc Res Ctr, NIH, Nanobiol Program, Ft Detrick, MD 21702 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA
关键词
sphingolipids; ceramide; therapeutics; inflammation; infectivity; immunity;
D O I
10.1007/s00018-005-5543-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The era of sphingolipid-based therapeutics is upon us. A large body of work has been accumulating that demonstrates the distinct biological roles of sphingolipids in maintaining a homeostatic environment and in responding to environmental stimuli to regulate cellular processes. It is thus necessary to further investigate alterations in sphingolipid-metabolism in pathological conditions and, in turn, try to exploit altered sphingolipid-me- tabolizing enzymes and their metabolites as therapeutic targets. This review will examine how advances in the fields of drug delivery, drug discovery, synthetic chemistry, enzyme replacement therapy, immunobiology, infectious disease and nanotechnology have delivered the potential and promise of utilizing and/or targeting sphingolipid metabolites as therapies for diverse diseases.
引用
收藏
页码:1017 / 1023
页数:7
相关论文
共 75 条
[1]   Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration [J].
Acharya, U ;
Patel, S ;
Koundakjian, E ;
Nagashima, K ;
Han, X ;
Acharya, JK .
SCIENCE, 2003, 299 (5613) :1740-1743
[2]   Ceramide content is increased in skeletal muscle from obese insulin-resistant humans [J].
Adams, JM ;
Pratipanawatr, T ;
Berria, R ;
Wang, E ;
DeFronzo, RA ;
Sullards, MC ;
Mandarino, LJ .
DIABETES, 2004, 53 (01) :25-31
[3]   The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity [J].
Bandhuvula, P ;
Tam, YY ;
Oskouian, B ;
Saba, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (40) :33697-33700
[4]   The role of sphingosine and ceramide kinases in inflammatory responses [J].
Baumruker, T ;
Bornancin, F ;
Billich, A .
IMMUNOLOGY LETTERS, 2005, 96 (02) :175-185
[5]   Immunotherapeutic potential for ceramide-based activators of iNKT cells [J].
Berkers, CR ;
Ovaa, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :252-257
[6]   Characterization of a ceramide kinase-like protein [J].
Bornancin, FR ;
Mechtcheriakova, D ;
Stora, S ;
Graf, C ;
Wlachos, A ;
Dévay, P ;
Urtz, N ;
Baumruker, T ;
Billich, A .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2005, 1687 (1-3) :31-43
[7]   Suppression of collagen-induced arthritis by natural killer T cell activation with OCK a sphingosine-truncated analog of α-galactosylceramide [J].
Chiba, A ;
Oki, S ;
Miyamoto, K ;
Hashimoto, H ;
Yamamura, T ;
Miyake, S .
ARTHRITIS AND RHEUMATISM, 2004, 50 (01) :305-313
[8]   Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? [J].
Cremesti, AE ;
Goni, FM ;
Kolesnick, R .
FEBS LETTERS, 2002, 531 (01) :47-53
[9]   Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate [J].
Cuvillier, O ;
Pirianov, G ;
Kleuser, B ;
Vanek, PG ;
Coso, OA ;
Gutkind, JS ;
Spiegel, S .
NATURE, 1996, 381 (6585) :800-803
[10]   Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death [J].
Dagan, A ;
Wang, CB ;
Fibach, E ;
Gatt, S .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2003, 1633 (03) :161-169